Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial

Antiviral Therapy

Volumn 2, Issue 1, 1997, Pages 39-46

  Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CLINICAL TRIAL; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV-1; HUMANS; LAMIVUDINE; MUTATION; PHENOTYPE; RNA, VIRAL; ZIDOVUDINE;

EID: 0030968830     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Ingrand D, Weber J, Boucher C. Loveday C, Robert C, Hill A, Cammack N & The Lamivudine European HIV Working Group. Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. AIDS 1995; 9:1323-1329.
2. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner S. Mulder J, Loveday C, Christopherson C, Kwok S. Sninsky J & Boucher C. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine. Journal of Infectious Diseases 1995; 171:1411-1419.
3. Tisdale M, Kemp SD, Parry NR & Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5656.
4. 3. 2nd National Conference on Human Retroviruses and Related Infections. Washington DC. USA. 28th January -1st February 1995. Abstr. 173.
5. Larder B, Kemp S & Harrigan P. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.